DRUCKEN

Cancer Immunotherapy

The contributions of UCT Mainz members to tumor immunology and cancer immunotherapy emanated from a four-decade-long investment in immunology. Activities range from excellent basic to translational research with early interventional trials. Immunotherapy represents a key translational research focus within the UCT Mainz and the entire Medical Faculty. Local, regional, national as well international collaboration platforms initiated by UCT Mainz members strengthen and promote translational research and provide substantial outreach capacities to pharmaceutical companies and regulatory authorities as well (FZI, Ci3, CIMT). Spinoff companies (BioNTech, TRON) form a hub to translate innovative concepts originating from the UCT Mainz research into clinical applications.

Achievements

Aims

To meet the challenges of multifaceted immune escape mechanisms mounted in the course of tumor-host interactions and by tumor plasticity, the cancer immunotherapy program of the UCT Mainz will encourage and support the development of combined modality approaches, e.g. target-specific immunotherapy together with checkpoint blockade, irradiation and/or signal transduction inhibition, and will foster the design of precision immunotherapy regimes involving diverse mechanisms of tumor recognition. In addition, we will establish a UCT Mainz-wide (re)biopsy program linked to an Immune Oncology Board to support translational research and innovative treatment strategies.

Working Groups

Department of Internal Medicine III - Hematology, Oncology and Pneumology:

Department of Dermatology:

BiomaTiCS:  

Institute of Immunology:

Institute of Translational Immunology:

Intitute of Molecular Medicine:

TRON:

Most significant publications since 2015